Figures & data
Figure 1. Distribution of the 411 substances over the different categories. Clockwise: Genotoxic carcinogen: positive in in vitro and in vivo genotoxicity/mutagenicity assays; Nongenotoxic carcinogen: substances with the reported treatment-related increase in incidence of benign or malignant tumors without in vivo evidence of genotoxicity; noncarcinogen: substance without reported treatment-related increase in incidence of benign or malignant tumors; Excluded: substance without sufficiently detailed or reliable tumor data available.
![Figure 1. Distribution of the 411 substances over the different categories. Clockwise: Genotoxic carcinogen: positive in in vitro and in vivo genotoxicity/mutagenicity assays; Nongenotoxic carcinogen: substances with the reported treatment-related increase in incidence of benign or malignant tumors without in vivo evidence of genotoxicity; noncarcinogen: substance without reported treatment-related increase in incidence of benign or malignant tumors; Excluded: substance without sufficiently detailed or reliable tumor data available.](/cms/asset/c8b43848-444e-4181-915a-db906e50ec4f/itxc_a_1841732_f0001_b.jpg)
Figure 3. Organ distribution of all 340 observed treatment-related tumors with a suspected nongenotoxic MOA. The category “Other” includes bone, skin, eye, and prostate tumors.
![Figure 3. Organ distribution of all 340 observed treatment-related tumors with a suspected nongenotoxic MOA. The category “Other” includes bone, skin, eye, and prostate tumors.](/cms/asset/cbcd1b2e-6b3b-41b0-9e79-0877709620e8/itxc_a_1841732_f0003_c.jpg)
Table 1. Summary table describing all discerned MOAs and MOA networks.